Document is current
Any future updates will be listed below
-
Authors
Alhalabi, Omar https://orcid.org/0000-0002-9658-2206
Chen, Jianfeng
Zhang, Yuxue
Lu, Yang https://orcid.org/0000-0001-9571-4679
Wang, Qi https://orcid.org/0000-0003-0858-9393
Ramachandran, Sumankalai
Tidwell, Rebecca Slack https://orcid.org/0000-0003-3041-8582
Han, Guangchun https://orcid.org/0000-0001-9277-2507
Yan, Xinmiao
Meng, Jieru
Wang, Ruiping
Hoang, Anh G.
Wang, Wei-Lien https://orcid.org/0000-0001-8809-4424
Song, Jian
Lopez, Lidia
Andreev-Drakhlin, Alex
Siefker-Radtke, Arlene https://orcid.org/0000-0002-6328-9599
Zhang, Xinqiao
Benedict, William F.
Shah, Amishi Y. https://orcid.org/0000-0002-9007-0621
Wang, Jennifer
Msaouel, Pavlos
Zhang, Miao
Guo, Charles C.
Czerniak, Bogdan
Behrens, Carmen
Soto, Luisa https://orcid.org/0000-0002-1253-630X
Papadimitrakopoulou, Vassiliki
Lewis, Jeff
Rinsurongkawong, Waree
Rinsurongkawong, Vadeerat
Lee, Jack https://orcid.org/0000-0001-5469-9214
Roth, Jack https://orcid.org/0000-0002-8955-1313
Swisher, Stephen https://orcid.org/0000-0002-3080-1920
Wistuba, Ignacio
Heymach, John https://orcid.org/0000-0001-9068-8942
Wang, Jing https://orcid.org/0000-0002-5398-0802
Campbell, Matthew T. https://orcid.org/0000-0003-1915-4491
Efstathiou, Eleni
Titus, Mark
Logothetis, Christopher J. https://orcid.org/0000-0002-6365-1711
Ho, Thai H. https://orcid.org/0000-0003-0023-2939
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Gao, Jianjun https://orcid.org/0000-0001-6138-4472
-
Funding
Funding for this research was provided by:
Conquer Cancer Foundation (14775)
UT | University of Texas MD Anderson Cancer Center
Doris Duke Charitable Foundation (2018097)
Andrew Sabin Family Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA254988-01A1)
- License Information
-
More Information
Article History
Received: 18 September 2020
Accepted: 10 March 2022
First Online: 4 April 2022
Competing interests
: Dr. Shah has honorarium with Pfizer, BMS, Exelixis and research funding from BMS, Eisai, and EMD Serono. Dr. Siefker-Radtke serves as a consultant for Janssen, Merck, the National Comprehensive Cancer Network, Lilly, Bristol-Myers Squibb, AstraZeneca, BioClin Therapeutics, Bavarian Nordic, Seattle Genetics, Nektar, Genentech, Inovio Pharmaceuticals, and EMD Serono. Dr. Siefker-Radtke has received research funding from the National Institute of Health, Michael and Sherry Sutton Fund for Urothelial Cancer, Janssen, Takeda, Bristol-Myers Squibb, BioClin Therapeutics, and Nektar. Dr. Campbell has served as a consultant or has provided non-branded educational lectures with honorarium with Pfizer, EMD Serono, AstraZeneca, Eisai, Apricity, Roche, Bristol Myers Squibb, and Merck. Dr. Gao serves as a consultant for ARMO Biosciences, AstraZeneca, Jounce, Nektar, and Pfizer. Dr. Msaouel has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Exelixis, and BMS, consulting for Axiom Healthcare Strategies, non-branded educational programs supported by Exelixis and Pfizer, and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics, Gateway for Cancer Research, and UT MD Anderson Cancer Center. Jack A. Roth has consultancy, stock, Genprex, Inc.; patents issued and pending. Dr. Ho has received honoraria from Exelixis, Genentech, EMD-Serono, Pfizer, Macrogenics, Cardinal Health, Ipsen, and Aveo. The remaining authors declare no conflicts of interest.
